Juglanin, a natural occurring flavonoid, is a JNK acticator, with inflammation and anti-tumor activities. Juglanin can induce apoptosis and autophagy on human breast cancer cells.
|Solubility (25°C)||DMSO 90 mg/mL|
|Storage||2-8°C, dry, sealed|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Fangxue Zhang, et al. Juglanin Inhibits Osteoclastogenesis in Ovariectomized Mice via the Suppression of NF-κB Signaling Pathways
 Guang Wang, et al. The Inhibitory Effects of Juglanin on Adipogenesis in 3T3-L1 Adipocytes
 Jian Zhao, et al. Juglanin suppresses oscillatory shear stress-induced endothelial dysfunction: An implication in atherosclerosis
 Ying-Hui Kong, et al. Juglanin administration protects skin against UVB‑induced injury by reducing Nrf2‑dependent ROS generation
 Xinxin Chen, et al. Juglanin inhibits IL-1β-induced inflammation in human chondrocytes
|Related JNK Products|
CC-90001 is a JNK (c-Jun N-terminal kinase) inhibitor that can be used as a Phase II clinical candidate to study idiopathic pulmonary fibrosis.
SU3327 is a potent, selective and substrate-competitive JNK inhibitor with an IC50 of 0.7 μM.
L-JNKI-1 is a cell-permeable peptide inhibitor specific for JNK.
JNK-IN-7 is a potent JNK inhibitor with IC50 of 1.5, 2 and 0.7 nM for JNK1, JNK2 and JNK3, respectively.
D-JNKI-1 (AM-111) is a highly potent and cell-permeable peptide inhibitor of JNK.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.